Antioxidants and narrow band-UVB in the treatment of vitiligo: A double-blind placebo controlled trial

Clinical and Experimental Dermatology

Volumn 32, Issue 6, 2007, Pages 631-636

  Dell'Anna, M L ^a   Mastrofrancesco, A ^a   Sala, R ^b   Venturini, M ^b   Ottaviani, M ^a   Vidolin, A P ^a   Leone, G ^a   Calzavara, P G ^b   Westerhof, W ^c   Picardo, M ^a  

^a SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^b SPEDALI CIVILI   (Italy)

^c Netherlands Institute for Pigment Disorders   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CATALASE; CYSTEINE DERIVATIVE; LIPOACID; LIPOACID COMBI; MEMBRANE LIPID; PLACEBO; POLYUNSATURATED FATTY ACID; PSORALEN; REACTIVE OXYGEN METABOLITE; THIOCTIC ACID; UNCLASSIFIED DRUG; UNSATURATED FATTY ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; OXYGEN SATURATION; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PIGMENT DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPIGMENTATION; SKIN PIGMENTATION; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; TREATMENT DURATION; ULTRAVIOLET B RADIATION; VITILIGO;

ADULT; ANTIOXIDANTS; ASCORBIC ACID; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; SEVERITY OF ILLNESS INDEX; SKIN PIGMENTATION; THIOCTIC ACID; TREATMENT OUTCOME; ULTRAVIOLET THERAPY; VITAMIN D; VITILIGO;

EID: 35348980740     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2007.02514.x     Document Type: Article

References (25)

1. Westerhof W, Nieuweboer-Krobotova L. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UVA. Arch Dermatol 1997 133 : 1525 8.
2. Kanvar AJ, Dogra S, Parsad D, Kumar B. Narrow-band UVB for the treatment of vitiligo: an emerging effective and well-tolerated therapy. Int J Dermatol 2005 44 : 57 60.
3. Leone G, Iacovelli P, Paro Vidolin A, Picardo M. Monochromatic excimer light 308 nm in the treatment of vitiligo: a pilot study. J Eur Acad Dermatol Venereol 2003 17 : 531 7.
4. Lu CS, Yu CL, Wu CS et al. Narrow-band ultraviolet-B stimulates proliferation and migration of cultured melanocytes. Exp Dermatol 2004 13 : 755 63.
5. Hartmann A, Lurz C, Hamm H et al. Narrow-band UVB 311 nm vs. broad-band UVB in combination with topical calcipotriol vs. placebo in vitiligo. Int J Dermatol 2005 44 : 736 42.
6. Grimes PE, Morris R, Avaniss-Aghajani E et al. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004 51 : 52 61.
7. Kullavanijaya P, Lim HW. Topical calcipotriene and narrowband ultraviolet B in the treatment of vitiligo. Photodermatol Photoimmunol Photomed 2004 20 : 248 51.
8. 2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J Invest Dermatol Symp Proc 1999 4 : 91 6.
9. Akyol M, Celik VK, Ozcelik S et al. The effects of vitamin E on the skin lipid peroxidation and the clinical improvement in vitiligo patients treated with PUVA. Eur J Dermatol 2002 12 : 24 6.
10. Patel DC, Evans AV, Hawk JLM. Topical pseudocatalase mousse and narrowband UVB phototherapy is not effective for vitiligo: an open, single-centre study. Clin Exp Dermatol 2002 27 : 641 4.
11. Taieb A. Intrinsic and extrinsic pathomechanisms in vitiligo. Pigment Cell Res 2000 13 : 41 7.
12. 2 accumulation alters tetrahydrobiopterin (6BH4) recycling in vitiligo: identification of a general mechanism in regulation of all 6BH4-dependent processes? J Invest Dermatol 2001 116 : 167 74.
13. Picardo M, Grammatico P, Roccella F et al. Imbalance in the antioxidant pool in melanoma and normal melanocytes from patients with melanoma. J Invest Dermatol 1996 107 : 322 6.
14. Dell'Anna ML, Maresca V, Briganti S et al. Mitochondrial impairment in peripheral blood mononuclear cells during the active phase of vitiligo. J Invest Dermatol 2001 117 : 908 13.
15. Paganelli R, Buttari B, Camera E et al. In vitro effects of nickel-sulphate on immune functions of normal and nickel allergic subjects: a regulatory role for zinc. J Trace Elem Med Biol 2003 17 : 11 15.
16. Dell'Anna ML, Urbanelli S, Mastrofrancesco A et al. Alterations of mitochondria in peripheral blood mononuclear cells of vitiligo patients. Pigment Cell Res 2003 16 : 553 9.
17. Claiborne A. Catalase activity. In : Handbook of Methods for Radical Research (Greenwald RA, ed). Boca Raton, FL : CRC, 1985 : 283 4.
18. Lenzi A, Gandini L, Maresca V et al. Fatty acid composition of spermatozoa and immature germ cells. Mol Hum Reprod 2000 6 : 226 31.
19. Maritim AC, Sanders RA, Watkins JB. Effects of alpha-lipoic acid on biomarkers of oxidative stress in streptozotocin-indiced diabetic rats. J Nutr Biochem 2003 14 : 288 94.
20. Bojunga J, Dresar-Mayert B, Usadel KH et al. Antioxidative treatment reverses imbalances of nitric oxide synthase isoform expression and attenuates tissue-cGMP activation in diabetic rats. Biochem Biophys Res Commun 2004 316 : 771 80.
21. Liu J, Killilea DW, Ames BN. Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L-carnitine and/or R-α-lipoic acid. Proc Natl Acad Sci USA 2002 99 : 1876 81.
22. Shapiro SS, Saliou C. Role of vitamins in skin care. Nutrition 2001 17 : 839 44.
23. Lapenna D, Ciofani G, Pierdomenico SD et al. Dihydrolipoic acid inhibits 15-lipoxygenase-dependent lipid peroxidation. Free Rad Biol Med 2003 35 : 1203 9.
24. Suh JH, Shenvi SV, Dixon BM et al. Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc Natl Acad Sci USA 2004 101 : 3381 6.
25. Pocernich CB, Butterfield DA. Acrolein inhibits NADH-linked mitochondrial enzyme activity: implications for Alzheimer's disease. Neurotox Res 2003 5 : 515 20.